How big is Vir Biotechnology, Inc.?

As of Jun 18, Vir Biotechnology, Inc. has a market capitalization of 705.01 million and reported net sales of 20.86 million, with a net profit of -577.66 million. Shareholder's funds are 1,150.38 million, and total assets are 1,423.59 million.

As of Jun 18, Vir Biotechnology, Inc. has a market capitalization of 705.01 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the company reported net sales of 20.86 million for the latest four quarters. During the same period, it recorded a net profit of -577.66 million.<BR><BR>As of Dec 24, the company's shareholder's funds amounted to 1,150.38 million, while its total assets were reported at 1,423.59 million.

What does Vir Biotechnology, Inc. do?

Vir Biotechnology, Inc. is a clinical-stage immunology company focused on developing treatments for serious infectious diseases. As of March 2025, it has a market cap of $705.01 million, with net sales of $3 million and a net loss of $121 million.

Overview: <BR>Vir Biotechnology, Inc. is a clinical-stage immunology company focused on developing treatments to treat and prevent serious infectious diseases, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 3 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -121 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 705.01 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.84 <BR>Return on Equity: -49.94% <BR>Price to Book: 0.68<BR><BR>Contact Details: <BR>Address: 499 Illinois St Ste 500, SAN FRANCISCO CA: 94158-2521 <BR>Tel: 1 415 9064324 <BR>Fax: 1 302 6365454 <BR>Website: https://www.vir.bio/

Should I buy, sell or hold Vir Biotechnology, Inc.?

Who are in the management team of Vir Biotechnology, Inc.?

As of March 2022, the management team of Vir Biotechnology, Inc. includes Dr. Vicki Sato (Independent Chairman), Dr. George Scangos (President and CEO), and several Independent Directors: Mr. Jeffrey Hatfield, Ms. Janet Napolitano, Mr. Robert More, Mr. Robert Nelsen, and Mr. Dipchand Nishar.

As of March 2022, the management team of Vir Biotechnology, Inc. includes Dr. Vicki Sato as the Independent Chairman of the Board, Dr. George Scangos as the President, Chief Executive Officer, and Director, along with several directors: Mr. Jeffrey Hatfield, Ms. Janet Napolitano, Mr. Robert More, Mr. Robert Nelsen, and Mr. Dipchand Nishar, all serving as Independent Directors.

Is Vir Biotechnology, Inc. overvalued or undervalued?

As of May 4, 2023, Vir Biotechnology, Inc. is considered risky and overvalued due to its negative P/E ratio, low Price to Book Value of 0.72, and an EV to EBITDA ratio of 0.23, alongside disappointing stock performance with a year-to-date return of -29.43% and a five-year return of -84.17%.

As of 4 May 2023, the valuation grade for Vir Biotechnology, Inc. has moved from expensive to risky, indicating a shift in perception regarding its financial health. The company appears to be overvalued based on its current metrics, particularly given its negative P/E ratio and a Price to Book Value of 0.72, which suggests that the stock is trading below its book value. Additionally, the EV to EBITDA ratio stands at 0.23, further reinforcing the notion of overvaluation in comparison to its peers.<BR><BR>In the peer comparison, Maravai Lifesciences Holdings, Inc. has a significantly higher EV to EBITDA ratio of -15.5085, while Zentalis Pharmaceuticals, Inc. shows a more favorable EV to EBITDA of 1.0769, indicating that Vir Biotechnology is lagging behind its competitors. The company's recent stock performance has been disappointing, with a year-to-date return of -29.43% compared to the S&P 500's 12.22%, and a staggering -84.17% return over the past five years, which underscores its struggles in the market.

Is Vir Biotechnology, Inc. technically bullish or bearish?

As of August 18, 2025, Vir Biotechnology, Inc. shows a mildly bearish trend with mixed signals from moving averages and indicators, and has underperformed the S&P 500 with a year-to-date return of -29.43%.

As of 18 August 2025, the technical trend for Vir Biotechnology, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by daily moving averages indicating a bearish trend, while weekly MACD and KST show a mildly bullish signal. The Bollinger Bands are bullish on the weekly but mildly bearish on the monthly, suggesting mixed signals. <BR><BR>In terms of performance, the stock has underperformed the S&P 500 across multiple periods, with a year-to-date return of -29.43% compared to the S&P 500's 12.22%, and a one-year return of -33.59% versus 17.14% for the benchmark.